NasdaqCM - Delayed Quote • USD
Immix Biopharma, Inc. (IMMX)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:00 PM EDT
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. | Co-Founder, CEO & Chairman | 637.5k | -- | 1973 |
| Mr. Gabriel Morris B.A. | CFO & Director | 637.5k | -- | 1987 |
| Mr. Sean Senn J.D., M.B.A., M.Sc., MBA, MSc | Co-Founder | -- | -- | -- |
| Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. | Scientific Co-Founder | -- | -- | 1947 |
| Mr. Ben H. Lyon J.D. | Executive VP & General Counsel | -- | -- | -- |
| Dr. Graham Ross FFPM, M.D. | Chief Medical Officer & Head of Clinical Development | -- | -- | 1960 |
| Mr. Nandan Oza B.S. | Head of Chemistry, Manufacturing & Control | -- | -- | 1962 |
| Dr. David Marks | Chief Medical Officer of Cell Therapy | -- | -- | -- |
| Mr. Gerhard Bauer | Head of Cell Thearpy Manufacturing | -- | -- | -- |
Immix Biopharma, Inc.
11400 West Olympic Boulevard
Suite 200
Los Angeles, CA 90064
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Corporate Governance
Immix Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Mar 29, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 20, 2024S-8: Offering RegistrationsSee Full Filing
- Feb 06, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 05, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 13, 202310-Q: Periodic Financial ReportsSee Full Filing
Upcoming Events
Upcoming Events Information Not Available
Related Tickers
MAIA MAIA Biotechnology, Inc.
2.9400
+9.70%
SPRC SciSparc Ltd.
1.3200
+4.76%
BPTH Bio-Path Holdings, Inc.
2.6800
+1.71%
ENSC Ensysce Biosciences, Inc.
0.5842
+1.69%
UNCY Unicycive Therapeutics, Inc.
1.0300
+6.19%
HOOK HOOKIPA Pharma Inc.
0.8933
+10.82%
CKPT Checkpoint Therapeutics, Inc.
1.4300
+0.70%
LGVN Longeveron Inc.
1.7500
+4.79%
HOTH Hoth Therapeutics, Inc.
1.1600
0.00%
MNOV MediciNova, Inc.
1.3100
-0.76%